Search - tctmd.com

Displaying 41 - 60 of 119

Sort: Relevancy | Date

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Daily News

PAD Significantly Ups Morbidity and Mortality in AMICS

L.A. McKeown

March 29, 2022

News Daily News

Statins Underprescribed in PAD Before and After Interventions

L.A. McKeown

December 03, 2021

News Opinion Conversations in Cardiology

Conversations in Cardiology: Do You Use Antibiotics in the Cath Lab?

October 12, 2021

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

News Conference News VIVA 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

L.A. McKeown

October 07, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Daily News

AHA Seeks to Drive Down Amputations 20% by 2030

L.A. McKeown

April 01, 2021

News Daily News

No Paclitaxel Death Signal in VA Data Out to 3 Years

L.A. McKeown

February 11, 2021

News Features

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

L.A. McKeown

December 24, 2020

News Daily News

‘Frailty Meter’ May Aid Treatment Decisions in Chronic Limb-Threatening Ischemia

L.A. McKeown

November 24, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

L.A. McKeown

September 03, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

L.A. McKeown

July 13, 2020

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Daily News

Veterans Study Shows Areas of Need for CLI Care

L.A. McKeown

February 17, 2020

Advertisement

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

PAD Significantly Ups Morbidity and Mortality in AMICS

Statins Underprescribed in PAD Before and After Interventions

Conversations in Cardiology: Do You Use Antibiotics in the Cath Lab?

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

June 2021 News Roundup

AHA Seeks to Drive Down Amputations 20% by 2030

No Paclitaxel Death Signal in VA Data Out to 3 Years

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

‘Frailty Meter’ May Aid Treatment Decisions in Chronic Limb-Threatening Ischemia

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

PAD Patients Undertreated With Statins Despite Elevated CV Risk

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

Veterans Study Shows Areas of Need for CLI Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content